Thomas S Higgins1,2, Arthur W Wu3, Elisa A Illing4, Kevin J Sokoloski5,6, Bree A Weaver7, Benjamin P Anthony4, Nathan Hughes8, Jonathan Y Ting4. 1. Department of Otolaryngology-Head and Neck Surgery and Communica-tive Disorders, University of Louisville, Louisville, Kentucky, USA. 2. Rhinology, Sinus, and Skull Base, Kentuckiana Ear, Nose, and Throat, Louisville, Kentucky, USA. 3. Department of Otolaryngology-Head and Neck Surgery, Cedars Sinai, Los Angeles, California, USA. 4. Department of Otolaryngology-Head and Neck Surgery, Indiana University, Indianapolis, Indiana, USA. 5. Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA. 6. Center for Predictive Medicine and Emerging Infectious Diseases, University of Louisville, Louisville Kentucky, USA. 7. Division of Infectious Diseases, Departments of Internal Medicine and Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana, USA. 8. Pharmacy Operations, Kindred Healthcare Support Center, Louisville, Kentucky, USA.
Abstract
OBJECTIVE: To provide a state of the art review of intranasal antiviral drug delivery and to discuss current applications, adverse reactions, and future considerations in the management of coronavirus disease 2019 (COVID-19). DATA SOURCES: PubMed, Embase, and Clinicaltrials.gov search engines. REVIEW METHODS: A structured search of the current literature was performed of dates up to and including April 2020. Search terms were queried as related to topics of antiviral agents and intranasal applications. A series of video conferences was convened among experts in otolaryngology, infectious diseases, public health, pharmacology, and virology to review the literature and discuss relevant findings. CONCLUSIONS: Intranasal drug delivery for antiviral agents has been studied for many years. Several agents have broad-spectrum antiviral activity, but they still require human safety and efficacy trials prior to implementation. Intranasal drug delivery has potential relevance for future clinical trials in the settings of disease spread prevention and treatment of SARS-CoV-2 and other viral diseases. IMPLICATIONS FOR PRACTICE: Intranasal drug delivery represents an important area of research for COVID-19 and other viral diseases. The consideration of any potential adverse reactions is paramount.
OBJECTIVE: To provide a state of the art review of intranasal antiviral drug delivery and to discuss current applications, adverse reactions, and future considerations in the management of coronavirus disease 2019 (COVID-19). DATA SOURCES: PubMed, Embase, and Clinicaltrials.gov search engines. REVIEW METHODS: A structured search of the current literature was performed of dates up to and including April 2020. Search terms were queried as related to topics of antiviral agents and intranasal applications. A series of video conferences was convened among experts in otolaryngology, infectious diseases, public health, pharmacology, and virology to review the literature and discuss relevant findings. CONCLUSIONS: Intranasal drug delivery for antiviral agents has been studied for many years. Several agents have broad-spectrum antiviral activity, but they still require human safety and efficacy trials prior to implementation. Intranasal drug delivery has potential relevance for future clinical trials in the settings of disease spread prevention and treatment of SARS-CoV-2 and other viral diseases. IMPLICATIONS FOR PRACTICE: Intranasal drug delivery represents an important area of research for COVID-19 and other viral diseases. The consideration of any potential adverse reactions is paramount.
Entities:
Keywords:
COVID-19; antiviral agents; coronavirus; nasal; nasopharynx; otolaryngology; public health; severe acute respiratory syndrome coronavirus 2
Authors: Lyn R Frumkin; Michaela Lucas; Curtis L Scribner; Nastassja Ortega-Heinly; Jayden Rogers; Gang Yin; Trevor J Hallam; Alice Yam; Kristin Bedard; Rebecca Begley; Courtney A Cohen; Catherine V Badger; Shawn A Abbasi; John M Dye; Brian McMillan; Michael Wallach; Traci L Bricker; Astha Joshi; Adrianus C M Boon; Suman Pokhrel; Benjamin R Kraemer; Lucia Lee; Stephen Kargotich; Mahima Agochiya; Tom St John; Daria Mochly-Rosen Journal: Front Immunol Date: 2022-06-01 Impact factor: 8.786
Authors: Victor B Hsue; Kyohei Itamura; Arthur W Wu; Elisa A Illing; Kevin J Sokoloski; Bree A Weaver; Benjamin P Anthony; Nathan Hughes; Jonathan Y Ting; Thomas S Higgins Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Amos C Lee; Yunjin Jeong; Sumin Lee; Haewook Jang; Allen Zheng; Sunghoon Kwon; John E Repine Journal: Front Immunol Date: 2021-05-19 Impact factor: 7.561
Authors: Klaus Fink; Andreas Nitsche; Markus Neumann; Marica Grossegesse; Karl-Heinz Eisele; Wojciech Danysz Journal: Viruses Date: 2021-03-24 Impact factor: 5.048